Biden Names Health Care Advisers with Strong Ties to Hill Democrats

The White House plans to release a revised administrative dispute resolution process for the 340B program this month.

Two health care policy experts with ties to congressional Democratic chairs influential on 340B matters have gone to work for the Biden White House.

Elizabeth Jurinka, most recently chief health adviser to Senate Finance Chair Ron Wyden (D-Ore.), on

Read More »

COVID-19 Relief Bill Includes Many Provisions Affecting 340B Providers

A screen capture of the Congressional Record for March 5 documenting the Senate's passage of nearly $2 trillion in pandemic relief.

The U.S. Senate voted 50 to 49 along party lines early Saturday morning to approve an amended version of the House’s $1.9 trillion COVID-19 relief bill. According to House Majority Leader Steny Hoyer’s (D-Md.) office, the House could vote on

Read More »

Hospitals Want Role in Three More Pharma Lawsuits Over 340B Contract Pharmacy

Hospital groups want to intervene in opposition to three more drug manufacturers' lawsuits against the federal government over 340B contract pharmacy requirements.

Hospital groups that recently filed a motion to intervene in opposition to drug manufacturer Eli Lilly’s lawsuit against the federal government over 340B contract pharmacy requirements also are trying to intervene in similar suits against the government by manufacturers AstraZeneca,

Read More »

Senator Cassidy Again Cites 340B in Opposing Becerra for HHS Secretary

U.S. Sen. Bill Cassidy (R-La.) yesterday criticized HHS Secretary-designate Xavier Becerra's lack of familiarity with 340B before voting in the Finance Committee against reporting Becerra's nomination favorably to the full Senate.

The U.S. Senate Finance Committee yesterday split 14-14 along party lines on whether to favorably report California Attorney General Xavier Becerra’s nomination to serve as U.S. Health and Human Services (HHS) secretary to the full Senate.

There is a 50-50

Read More »

Orphan Drug Study’s Authors Say Findings May Warrant Lifting 340B Exemption

Humira, one of the 15 partial orphan drugs examined in the new study in Health Affairs, had $13.7 billion in sales in 2018.

More than 70 percent of U.S. spending on top-selling “partial orphan drugs”—drugs for rare diseases that also are approved to treat common diseases—is for non-orphan indications, a study in latest edition of Health Affairs concludes.

Makers of partial orphan drugs

Read More »

Senate Democrats Soften, But Don’t Yank, COVID Relief Bill’s Medicaid Rebate Language

In a concession to drug companies, Senate Democrats reportedly have agreed to delay by one year—from Jan. 1, 2023 to Jan. 1, 2024—the effective date of language in the $1.9 trillion COVID-19 relief bill that might lead to 340B ceiling

Read More »

DOJ Opposes Sanofi’s Move to Head Off 340B Dispute Resolution in Contract Pharmacy Battle

The U.S. Justice Department (DOJ) has slammed a second drug manufacturer’s motion before a federal court to block implementation of the 340B program’s new administrative dispute resolution (ADR) process.

First, on Feb. 16 in a federal district court in

Read More »

340B Providers Cheer Bipartisan House Letter to HHS on Manufacturer Actions

Safety-net hospitals, health centers, and HIV/AIDS clinics yesterday applauded the 226 U.S. representatives—more than half of the House’s members—who signed Friday’s bipartisan letter to U.S. Health and Human Services (HHS) Acting Secretary Norris Cochran seeking “immediate action to ensure that

Read More »

Huge COVID Relief Bill That Would Lift Medicaid Rebate Caps Moves to Senate

The U.S. House on Saturday passed a $1.9 trillion COVID-19 relief bill with language that might lead to 340B ceiling prices on some branded drugs being set lower than the drugs’ average manufacturer price (AMP).

The bill, H.R. 1319,

Read More »

226 Bipartisan U.S. House Members Ask HHS to Stop Pharma From Unilaterally Changing 340B

Slightly more than half of all U.S. Representatives signed the Feb. 26 letter to HHS urging immediate action to stop drug manufacturers from making unilateral changes to 340B | Shutterstock

Two hundred and twenty six U.S. House members—173 Democrats and 57 Republicans—have signed a letter to U.S. Health and Human Services (HHS) Acting Secretary Norris Cochran asking him “to take immediate action to ensure that manufacturers are prohibited from imposing

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live